FI104373B - Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 7-aminosubstituoituja 10,11-metyleenidioksi- tai 10,11-etyleenidioksi-kamptotekiinijohdannaisia - Google Patents

Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 7-aminosubstituoituja 10,11-metyleenidioksi- tai 10,11-etyleenidioksi-kamptotekiinijohdannaisia Download PDF

Info

Publication number
FI104373B
FI104373B FI924878A FI924878A FI104373B FI 104373 B FI104373 B FI 104373B FI 924878 A FI924878 A FI 924878A FI 924878 A FI924878 A FI 924878A FI 104373 B FI104373 B FI 104373B
Authority
FI
Finland
Prior art keywords
compound
formula
camptothecin
ethylenedioxy
methylenedioxy
Prior art date
Application number
FI924878A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI924878A (fi
FI924878A0 (fi
Inventor
Michael Joseph Luzzio
Jeffrey M Besterman
Michael G Evans
Peter Leslie Myers
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of FI924878A0 publication Critical patent/FI924878A0/fi
Publication of FI924878A publication Critical patent/FI924878A/fi
Application granted granted Critical
Publication of FI104373B publication Critical patent/FI104373B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
FI924878A 1991-10-29 1992-10-28 Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 7-aminosubstituoituja 10,11-metyleenidioksi- tai 10,11-etyleenidioksi-kamptotekiinijohdannaisia FI104373B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78427591A 1991-10-29 1991-10-29
US78427591 1991-10-29
US82672992A 1992-01-28 1992-01-28
US82672992 1992-01-28

Publications (3)

Publication Number Publication Date
FI924878A0 FI924878A0 (fi) 1992-10-28
FI924878A FI924878A (fi) 1993-04-30
FI104373B true FI104373B (fi) 2000-01-14

Family

ID=27120258

Family Applications (3)

Application Number Title Priority Date Filing Date
FI924878A FI104373B (fi) 1991-10-29 1992-10-28 Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 7-aminosubstituoituja 10,11-metyleenidioksi- tai 10,11-etyleenidioksi-kamptotekiinijohdannaisia
FI982185A FI982185A (fi) 1991-10-29 1998-10-08 Vesiliukoiset kamtotesiinijohdokset
FI20021090A FI20021090A (fi) 1991-10-29 2002-06-07 Vesiliukoiset kamptotesiinijohdokset

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI982185A FI982185A (fi) 1991-10-29 1998-10-08 Vesiliukoiset kamtotesiinijohdokset
FI20021090A FI20021090A (fi) 1991-10-29 2002-06-07 Vesiliukoiset kamptotesiinijohdokset

Country Status (25)

Country Link
EP (1) EP0540099B1 (de)
JP (2) JP3020760B2 (de)
KR (1) KR100246154B1 (de)
CN (1) CN1072683A (de)
AP (1) AP306A (de)
AT (1) ATE136898T1 (de)
AU (1) AU657007B2 (de)
CA (1) CA2081580A1 (de)
CZ (1) CZ284023B6 (de)
DE (1) DE69209969T2 (de)
DK (1) DK0540099T3 (de)
ES (1) ES2086643T3 (de)
FI (3) FI104373B (de)
GR (1) GR3020120T3 (de)
HU (2) HU217970B (de)
IL (1) IL103571A (de)
IS (1) IS1708B (de)
MX (1) MX9206211A (de)
MY (1) MY108261A (de)
NO (1) NO302073B1 (de)
NZ (1) NZ244914A (de)
OA (1) OA09767A (de)
RU (1) RU2119921C1 (de)
SK (1) SK323792A3 (de)
TW (1) TW221994B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
ES2186812T3 (es) * 1993-01-15 2003-05-16 Stehlin Foundation For Cancer Tratamiento oral o intramuscular del cancer pancreatico con s-camptotecina insoluble en agua de la forma de anillo de lactona cerrado.
US5369127A (en) * 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
MX9403275A (es) * 1993-05-03 1995-01-31 Smithkline Beecham Corp Metilendioxi[3,'4':6,7]indolizino-[1,2-b]quinolinonas substituidas.
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
IT1269862B (it) * 1994-05-30 1997-04-15 Indena Spa Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
KR960029336A (ko) 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5496952A (en) * 1995-02-07 1996-03-05 North Carolina State University Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
ATE275132T1 (de) * 1995-06-27 2004-09-15 Takeda Chemical Industries Ltd 4-acylamino(halogen)alkyl-chinolin derivate, deren herstellung und deren verwendung als melatonin-agonisten
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
WO1997019085A1 (en) * 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
TW464652B (en) 1996-10-30 2001-11-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6559309B2 (en) * 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
CZ298259B6 (cs) 2000-02-28 2007-08-08 Aventis Pharma S. A. Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
JP2004517821A (ja) 2000-10-27 2004-06-17 アベンティス・ファーマ・ソシエテ・アノニム 癌治療のためのカンプトセシン及びスチルベン誘導体からなる組合せ
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
WO2012050591A1 (en) 2010-10-15 2012-04-19 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
AU2007232206B2 (en) 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
CN101407524B (zh) * 2007-10-09 2012-07-18 江苏先声药物研究有限公司 噁嗪骈喜树碱衍生物及其制备方法和用途
CN100592871C (zh) * 2008-03-14 2010-03-03 浙江林学院 一种杀虫剂组合物及其加工方法
ES2373172B1 (es) * 2010-07-16 2012-12-10 Consejo Superior De Investigaciones Científicas (Csic) Proceso de obtención de derivados solubles en agua de 20 (s) camptotecina como agentes antitumorales.
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
US20190343828A1 (en) * 2018-04-06 2019-11-14 Seattle Genetics, Inc. Camptothecin peptide conjugates
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
AU2022330892A1 (en) * 2021-08-19 2024-03-21 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Camptothecin derivative, and pharmaceutical composition and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
JPH05222048A (ja) 1993-08-31
AP9200439A0 (en) 1992-10-31
HU217970B (hu) 2000-05-28
FI982185A0 (fi) 1998-10-08
NO924158D0 (no) 1992-10-28
JP3020760B2 (ja) 2000-03-15
FI924878A (fi) 1993-04-30
JP3229298B2 (ja) 2001-11-19
IS3936A (is) 1993-04-30
HUT65719A (en) 1994-07-28
TW221994B (de) 1994-04-01
FI20021090A (fi) 2002-06-07
EP0540099A1 (de) 1993-05-05
CZ284023B6 (cs) 1998-07-15
IL103571A0 (en) 1993-03-15
OA09767A (en) 1993-11-30
MY108261A (en) 1996-09-30
SK279298B6 (sk) 1998-09-09
JP2000109475A (ja) 2000-04-18
SK323792A3 (en) 1998-09-09
DE69209969D1 (de) 1996-05-23
CZ323792A3 (en) 1993-10-13
CA2081580A1 (en) 1993-04-30
DE69209969T2 (de) 1996-09-12
NO302073B1 (no) 1998-01-19
ES2086643T3 (es) 1996-07-01
DK0540099T3 (da) 1996-06-17
CN1072683A (zh) 1993-06-02
IL103571A (en) 1998-01-04
ATE136898T1 (de) 1996-05-15
FI924878A0 (fi) 1992-10-28
KR100246154B1 (ko) 2000-04-01
IS1708B (is) 1998-12-16
GR3020120T3 (en) 1996-08-31
NZ244914A (en) 1995-01-27
EP0540099B1 (de) 1996-04-17
FI982185A (fi) 1998-10-08
AP306A (en) 1994-01-28
MX9206211A (es) 1993-05-01
RU2119921C1 (ru) 1998-10-10
NO924158L (no) 1993-04-30
AU2738592A (en) 1993-05-06
HU211349A9 (en) 1995-11-28
AU657007B2 (en) 1995-02-23
HU9203384D0 (en) 1993-01-28

Similar Documents

Publication Publication Date Title
FI104373B (fi) Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 7-aminosubstituoituja 10,11-metyleenidioksi- tai 10,11-etyleenidioksi-kamptotekiinijohdannaisia
US5559235A (en) Water soluble camptothecin derivatives
US5342947A (en) Preparation of water soluble camptothecin derivatives
US6100273A (en) Water soluble camptothecin derivatives
AU652728B2 (en) Camptothecin analogs as potent inhibitors of human colorectal cancer
RU2294932C2 (ru) Новые производные индола со сродством к рецептору 5-ht6
EP0496634A1 (de) Substituierte Phenyl-1,3-dioxolochinolinderivate und ihre Verwendung als Antitumormittel
US5364858A (en) Camptothecin analogs as potent inhibitors of topoisomerase I
EP0912534A1 (de) Muscarin-antagonisten
EP0696285A1 (de) Wasserloesliche camptothecinderivate und ihre verwendung als antitumormittel
KR100453979B1 (ko) 인데노인돌론 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
EP1553911B1 (de) 2-heterosubstituierte 3-aryl-4-h-1-benzopyran-4-one als neue therapeutika bei brustkrebs
KR100503518B1 (ko) 2-(4-알킬-1-피페라지닐)-벤즈알데하이드 및 -벤질리데닐화합물의 제조 방법
CN115340526B (zh) 邻二甲酰亚胺类化合物及其药物组合物、制备方法和用途
PL173684B1 (pl) Pochodne kamptotecyny i sposób wytwarzania pochodnych kamptofecyny
CZ281049B6 (cs) Antipsychoticky účinné benzodioxanové deriváty
SI9300183A (sl) Vodotopni kamptotecinski derivati
KR20020069514A (ko) (-)-시스-2-(2-클로로페닐)-5,7-디하이드록시-8[4ｒ-(3ｓ-하이드록시-1-메틸)피페리디닐]-4ｈ-1-벤조피란-4-온의에탄올 용매화물
EP0770601A1 (de) Propenon-derivate